ACR20 | DAS28 | PASI75 | ||||
---|---|---|---|---|---|---|
Biomarker | OR | p Value | OR | p Value | OR | p Value |
Baseline | ||||||
Adiponectin | 1.681 | NS | 2.296 | 0.019 | 1.969 | 0.035 |
Apolipoprotein CIII | 0.865 | NS | 1.459 | NS | 2.397 | 0.048 |
ENRAGE | 1.133 | NS | 2.455 | 0.006 | 0.717 | NS |
IgA | 1.013 | NS | 1.849 | 0.023 | 1.279 | NS |
IGF-1 | 1.234 | NS | 1.668 | NS | 0.272 | 0.015 |
IL-16 | 0.858 | NS | 2.330 | 0.028 | 1.063 | NS |
Insulin | 0.803 | NS | 0.706 | 0.018 | 0.876 | NS |
Myeloperoxidase | 1.323 | NS | 1.743 | 0.019 | 0.720 | NS |
PAP | 2.528 | 0.034 | 2.761 | 0.021 | 0.927 | NS |
SGOT | 0.536 | NS | 0.274 | 0.001 | 1.471 | NS |
VEGF | 1.665 | 0.042 | 2.338 | 0.008 | 1.133 | NS |
Pyridinoline | 0.198 | 0.008 | 0.344 | NS | 0.777 | NS |
MMP-3 | 1.115 | NS | 1.264 | NS | 0.509 | NS |
Change from baseline to week 4 | ||||||
CRP | 0.708 | 0.038 | 0.700 | NS | 0.851 | NS |
Cancer antigen 125 | 0.286 | 0.034 | 0.293 | 0.046 | 0.929 | NS |
Carcinoembryonic Antigen | 0.054 | 0.024 | 0.341 | NS | 0.461 | NS |
CD40 | 0.516 | NS | 0.265 | 0.040 | 2.171 | NS |
CD40 ligand | 0.773 | NS | 0.558 | 0.027 | 1.100 | NS |
ENRAGE | 0.589 | 0.029 | 0.622 | NS | 1.319 | NS |
ICAM-1 | 0.387 | NS | 0.178 | 0.028 | 2.280 | NS |
IL-16 | 0.305 | 0.047 | 0.191 | 0.016 | 1.224 | NS |
MDC | 0.118 | 0.009 | 0.324 | NS | 0.233 | NS |
MIP-1α | 0.976 | NS | 0.319 | 0.015 | 1.033 | NS |
MIP-1β | 0.544 | NS | 0.127 | 0.009 | 0.899 | NS |
Myeloperoxidase | 0.806 | NS | 0.589 | 0.014 | 1.077 | NS |
PSA-free | 0.343 | NS | 0.167 | 0.025 | 0.604 | NS |
PAP | 0.220 | 0.009 | 0.144 | 0.003 | 1.243 | NS |
SGOT | 1.150 | NS | 2.251 | 0.040 | 0.459 | 0.044 |
TNF receptor II | 0.158 | NS | 0.090 | 0.032 | 0.500 | NS |
VEGF | 0.395 | NS | 0.196 | 0.009 | 1.836 | NS |
TNFα serum | 0.592 | NS | 0.400 | NS | 0.039 | <0.001 |
ICAM-1 | 0.055 | 0.044 | 0.235 | NS | 0.428 | NS |
Values were significant if they were p<0.05.
ACR20, American College of Rheumatology 20% improvement response; CRP, C-reactive protein; DAS28, disease activity score in 28 joints; ICAM, intercellular adhesion molecule; IL, interleukin; IG, immunoglobulin; MDC, monocyte/macrophage-derived chemokine; MIP-1, macrophage inflammatory protein 1; MMP, matrix metalloproteinase; NS, not significant; PAP, prostatic acid phosphatase; PSA, prostate-specific antigen; PASI75, 75% improvement in the psoriasis area and severity index score; SGOT, serum glutamic oxaloacetic transaminase; TNF, tumour necrosis factor; VEGF, vascular endothelial growth factor.